In this context, the PETAL study assessed a treatment escalation strategy using an intensive Burkitt’s lymphoma protocol, consisting of six cycles of an intensive methotrexate and cytarabine-based regimen in PET-positive patients after two cycles of R-CHOP, compared to receiving six additional cycles of standard R-CHOP [21]. This evidence concerns the gene DDIT3 and Burkitt lymphoma.